The ARIES HeartMate 3 Pump IDE Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 628 participants.

Also called NCT04069156

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose supportive care
Phase
Not applicable
Enrolled
  • 628 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04069156
Other papers using this trial's data
  • Concomitant Surgical Procedures and Aspirin Avoidance With Left Ventricular Assist Device Therapy JACC. Heart failure, 2025-07 DOI, PubMed 40208135
  • Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial JACC. Heart failure, 2026-03 DOI, PubMed 41258850

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Canada, Czechia, France, Italy, Kazakhstan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04069156. Randomized; quadruple masking; primary purpose supportive care. Start 2020-07-14 (actual); primary completion 2023-08-10 (actual). Results posted on 2025-03-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The ARIES HeartMate 3 Pump IDE Study
Condition
Heart Failure
Intervention (Device)
LVAD Implant
Intervention (Drug)
Aspirin 100mg
Intervention (Drug)
Placebo oral tablet
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct04069156
Content hash
a56e6a55fa2f2dd9fe3edc5d6f19614b509095b3f630b1248b046198b8c6b834